Anti-insulin receptor monoclonal antibodies can activate selected naturally occurring mutated human insulin receptors, raising the prospect of novel therapy for lethal recessive insulin resistance. 
Introduction
Insulin downregulates catabolic and activates anabolic pathways, suppresses apoptosis and promotes mitosis in response to nutrient ingestion by activating a homodimeric receptor tyrosine kinase (1, 2) . Human loss-of-function mutations in the insulin receptor (INSR) were first reported in 1988 (3, 4) , since when more than 100 alleles causing severe insulin resistance have been described (5) . Biallelic INSR mutations produce extreme congenital insulin resistance, clinically described as Donohue or Rabson Mendenhall syndromes (OMIM#246200 or 262190), both featuring impaired linear growth, soft tissue overgrowth and severe metabolic derangement, with demise usually in the first 3 years of life in Donohue syndrome.
Some INSR mutations impair receptor processing and cell surface expression. Many mutations, however, are well expressed, but exhibit impaired insulin binding, impaired signal transduction, perturbed recycling kinetics, or a combination of these (6) . It has been suggested that the signaling defect of mutant receptors at the cell surface might be circumvented by binding of anti-receptor antibodies, and proof of this principle was provided for two mutations, one in a cell culture model and one as solubilised receptor (7, 8) .
Therapeutic use of antibodies has now become well established. In particular, antibodies have been developed as cancer therapeutics to block receptor signaling (9) , although therapeutic antibodies are also increasingly being developed for non-cancer indications (10) . Interest in the potential of therapies targeting the INSR has recently rekindled, with inhibitory antibodies in Phase 1 human trials (11) , and stimulatory antibodies shown to ameliorate diabetes in rodents (12) (13) (14) (15) and primates (16) .
Given these developments, and the high clinical need in recessive insulin receptoropathy, we assessed the effect of monoclonal anti-INSR antibodies (17) (18) (19) (20) (21) on signaling by a series of diseasecausing mutant INSR in cell-based models. We demonstrate that INSR antibodies bind many mutant receptors, triggering autophosphorylation and downstream signaling. For mutant receptors with selective defects in insulin binding, the signaling response to antibody may exceed that elicited by Page 3 of 31 insulin, suggesting that antibodies might be used therapeutically as surrogate ligands to ameliorate recessive conditions for which there is currently no effective therapy.
Materials and Methods

Cell lines and culture conditions
Culture media for CHO Flp-IN cells (Invitrogen) and 3T3-L1 pre-adipocytes (Zenbio) are shown in Table S1 . 3T3-L1 pre-adipocytes were grown to confluence and differentiation was induced by Differentiation medium 1 for 72h before changing to Differentiation medium 2 for a further 72h.
Adipocytes were maintained in Adipocyte medium containing 1μM insulin ± 1 μg/ml doxycycline.
Experiments were undertaken at day 14 or 16 of differentiation as indicated.
hINSR mutant expression constructs and generation of CHO FlpIN hINSR cells
Mutation numbering refers to mature hINSR ex11+ (GenBank M1005.1), which was amplified from pDNR-Dual using primers incorporating a C-terminus myc tag. Sub-cloning is detailed in Table   S2 . Mutations were generated with the Quickchange II XL kit (Stratagene). CHO Flp-IN cells were transfected with pCDNA5/FRT/TO/hINSR and pOG44 using Lipofectamine 2000 (Invitrogen). The polyclonal population surviving Hygromycin B selection was used for experiments.
Lentivirus production and infection of 3T3-L1 preadipocytes
Target sequences, primers, vectors and sub-cloning are detailed in Table S3 . Virus containing concatenated miR-shRNAs was packaged and concentrated as described by Shin et al (22) . Single cell 3T3-L1 preadipocyte clones were generated by infection with the lowest MOI of virus needed to confer hygromycin B resistance. Several clones per line were characterised for both endogenous Insr knockdown and adipocyte differentiation by Oil-Red-O staining (23) . For hINSR re-expression studies, 3T3-L1 MmINSRKD cells were infected with virus containing myc-tagged hINSR transgenes, the lowest MOI needed to confer G418 resistance being used to generate polyclonal populations. hINSR expression was confirmed by Sanger sequencing of cDNA.
Flow cytometry
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CHO Flp-IN hINSR cells were blocked by 5%FCS/ FACS buffer (Table S4) before incubation   with primary antibodies for 1h at 4 o C. Bound antibodies were detected using FITC-conjugated antimouse IgG and a BD FACSCalibur Flow Cytometer (530nm/30nm bandwidth filter, Benton Dickinson). Stacked overlay histograms were visualised with FCS Express 6 Plus (DeNovo Software, USA).
Receptor Autophosphorylation Assays
CHO Flp-IN hINSR cells were washed twice and serum starved (16h) before stimulation with insulin, antibody or both, for 10min at 37 o C/5%CO 2 and lysis on ice in lysis buffer (Table S4) .
Receptors were captured overnight at 4 o C on anti-myc antibody 9E10-coated white Greiner Lumitrac 600 96-well plates. Phosphotyrosines on immunocaptured receptors were detected with biotinconjugated 4G10 platinum phospho-tyrosine antibody and Europium-labelled streptavidin. DELFIAenhancement solution was added and time-resolved fluorescence measured (Ex:340nm/Em:615nm).
Downstream signal activation
3T3-L1 adipocytes were washed twice in DMEM, serum starved for 16h in DMEM/0.5%BSA/1μg/ml DOX, and then treated for 10min at 37 o C/5%CO 2 with 10nM insulin, 10nM antibody, or both in DMEM/0.5%BSA. Cells were washed, snap frozen and lysed on ice before two rounds of centrifugation at 16.1x RCF at 4 o C for 15min to pellet insoluble material and separate lipids prior to Western blotting.
Western blotting
10µg of total lysate was resolved on NuPAGE 4-12% bis-tris gels or E-PAGE 48 8% gels (Life Technologies) and transferred to nitrocellulose by iBlot (Life Technologies). Membranes were blocked in 3% BSA/TBST before overnight incubation at 4 o C with primary antibodies (Table S5) . 
Glucose Uptake
3T3-L1 adipocytes were washed twice (DMEM), serum-starved for 16h in low-glucose DMEM/0.2% BSA/1μg/ml DOX, washed twice in PBS and then stimulated for 30min at 37 o C/5%CO 2 with 10nM insulin, 10nM antibody or both in KRPH/0.2%BSA buffer (Table S4) . Cells were incubated with 1mM 2-Deoxy-d-glucose for 5min at 37 o C/5%CO 2 before washing (PBS), lysing with 0.1M NaOH, and snap freezing. Glucose uptake was measured by the fluorescence method of Yamamoto et al (24) .
Statistical Analysis
One-way ANOVAs with Tukey's multiple comparisons test were performed with GraphPad Prism 6 (GraphPad Software). Error bars represent SEM or SD as indicated. All experiments were performed at least three times.
Results
Assessment of mutant INSR cell surface expression and antibody binding
Eleven INSR mutations were selected for study (Table S6) . Eight were based on evidence of cell surface expression, prioritizing mutations identified in multiple reports to maximize likely tyrosine kinase mutation (25, 26) , and the L62P mutation which severely impairs processing (27) , were added as controls. Figure 1A displays the extracellular INSR mutations mapped onto the crystal structure of the INSR (28) . Four mouse monoclonal anti-human INSR antibodies were used, which had previously all been shown to have partial agonist activity at wild type (WT) receptors, but different effects on kinetics and affinity of insulin binding ( Table 1 Table S7 , data not shown for non-responsive P1178L). R118C, I119M, and K460E
however showed autophosphorylation comparable to WT and so were not studied further. Altered insulin EC50 was discernible only for S323L (Table S7) Table S7 ), however for S323L the maximal autophosphorylation response to 83-7 and 83-14 was similar to that with insulin, while D707A was activated by antibodies but not insulin.
We next evaluated responses to insulin plus 10nM antibody, based on evidence suggesting this concentration elicits the maximal response (19, 21) . In the presence of antibodies 83-7 and 83-14 the maximal response of WT and mutant INSRs to insulin was increased without affecting potency (although EC50 values were not precisely determined) ( Figure 2 , Table S7 ). This was observed across all mutant receptors except the kinase-dead P1178L (25, 26) . Again, antibodies 18-44 and 18-146 elicited smaller effects.
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Generation of a novel adipocyte cell model of insulin receptoropathy 
Activation of signaling downstream from mutant INSRs by insulin and antibody
Plasma insulin concentration in human insulin receptoropathies usually lies between 0.3 and 3 nM in the fasting state (Table S6) , and at least an order of magnitude higher when fed. We focused on an insulin concentration of 10nM, mimicking the fed disease state. WT INSR autophosphorylation was strongly induced by insulin, but was undetectable after receptor knockdown alone (Figure 4 ). (7)), and, independently, that one bivalent antibody increased glycogen synthesis acting via a mutant receptor expressed in intact cells (S232L (18)). We extend these limited previous findings with systematic characterization of multiple receptor mutants and antibodies in two cellular systems, with several readouts of physiologically important responses including adipocyte glucose uptake.
One of the mutants assessed, F248C, is novel. It lies close to the well-studied R252C mutant, which is expressed but exhibits impaired internalization after insulin exposure. F248C shows only minor reduction in cell surface expression, but insulin-stimulated receptor autophosphorylation and downstream signaling are severely impaired. Across known mutants our data generally agree with prior studies. Assay of receptor autophosphorylation in CHO cells using immunocapture of myctagged receptor prior to immunoassay demonstrated signaling defects more clearly than phosphotyrosine immunoblotting in the 3T3-L1 overexpression system. This is likely due to the inherently greater dynamic range of immunoassay allied to use of a generic anti-phosphotyrosine antibody, with different degrees of receptor overexpression between the two models possibly also contributing.
We confirmed that S323L and F382V receptors can be partially activated by antibodies, and extended these observations to a wider range of mutants. Previous studies suggest that receptor activation by antibody depends on receptor cross-linking rather than reaction at specific epitopes (20) . exert insulin-like activity on primary human adipocytes (21) . Differences among antibodies are likely to reflect differences of affinity and/or steric constraints on cross-linking receptors in intact cells.
The mutants showing the largest antibody response were S323L and D707A, both being activated by antibodies similarly to WT receptor, and to a greater extent than by insulin. Such mutants with 'pure' insulin binding defects are particularly attractive therapeutic targets. Other mutants studied in both cell systems (P193L, F248C, R252C, and F382V) all showed some activation of AKT, GSK3, AS160 and glucose uptake by antibodies. In these cases responses were less than for WT receptor or those induced by insulin although it is unclear that the conditions studied optimally model the in vivo environment, and receptor overexpression is likely to have mitigated some functional defects. Testing the therapeutic potential of antibodies against such mutants is warranted in vivo, where antibody signalling may be prolonged compared to insulin signalling due to slower receptor internalisation. Indeed, a previously studied anti insulin receptor antibody showed markedly greater hypoglycemic effects in vivo in wild type animals than had been apparent in cell culture models (14) .
Antibodies would be a particularly appealing therapeutic proposition were they to exhibit synergy with insulin in receptor stimulation, amplifying insulin action rather than simply imposing a Early cellular studies of antibody-induced insulin receptor activation were interpreted as suggesting that antibodies elicit greater downstream responses than expected from low levels of receptor autophosphorylation (17, (34) (35) (36) . These observations were later argued to have a methodological basis, hinging on lower sensitivity in detecting tyrosine phosphorylation than
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downstream signaling (37, 38) . This is in part because signal amplification is an inherent property of signal transduction cascades. Our observation of apparent "escape" from signaling inhibition in the face of efficient Insr knockdown in 3T3-L1 adipocytes supports this contention, as activation of residual receptors is undetectable directly but is observable downstream due to signal amplification.
Importantly, receptor activation by antibodies leads to selective AKT phosphorylation, which is critical for metabolic actions of insulin, with little or no ERK phosphorylation. As activation of the RAS/RAF/MEK/ERK pathway is mitogenic, this is an encouraging property of antibodies for translational purposes, suggesting that they may exert metabolic benefits without undue mitogenic activity. Similar dissociation between activation of AKT and ERK has also been observed following INSR activation by the peptide ligand S597 (39) and in previous studies with anti-receptor antibodies (40) . The mechanism underlying such pathway-specific activation is poorly understood, although IRS proteins may be preferentially phosphorylated by plasma membrane-associated receptor (41, 42) , whereas receptor internalization is required for full ERK activation (42, 43) . This suggests that differential signaling may relate to cell surface retention of antibody-bound receptors.
In summary, multiple monoclonal antibodies can bind and activate a range of mutated cell surface insulin receptors to a potentially highly clinically significant degree. Prior experience in wild type animals (14) and theoretical considerations argue that effects of anti-INSR antibodies in vivo may be greater than those in cells, and so further studies of mutant human INSR in animal models are warranted. The murine antibodies studied are particularly amenable to this, as their effect will not be attenuated by host immune responses to human antibodies. Later translation to humans will require humanisation of the antibodies, however many current therapeutic antibodies are humanised or chimeric versions of murine antibodies (9) , and moreover humanisation has already been reported for a different purpose for 83-14, with no deleterious consequences for wild type receptor binding (44, 45) . This suggests a practical route to future testing of anti-INSR antibodies in severely unwell infants with recessive lethal receptoropathy where the potential clinical benefits are transformational, and also raises the prospect of later evaluation of antibodies as novel ultralong-acting insulin mimetics in 
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